Coronary heart disease is one of the leading causes of death in the developed world as well as in the developing countries like Bangladesh. A population based study found the prevalence of ischemic heart disease to be 6.5 per thousand in Bangladesh. 1 PCI has become one of the cardinal treatment strategies for coronary artery disease. Technical advances have expanded the capabilities of balloon angioplasty. Despite these advances, the incidence of post procedural cardiac marker elevation has not substantially decreased since the first serial assessment 20 years back. As of now, these post procedural cardiac marker elevations are considered 'peri-procedural myocardial injury' (PMI) with worse long-term outcome. 2 PMI is synonymous with peri-procedural myocardial infarction in most of the cases. In patients with normal baseline values, elevations of cardiac marker level above 99 th percentile of upper reference limit are indicative of periprocedural myocardial necrosis. By convention, increases of bio-markers greater than 3×99th percentile upper reference limit have been designated as defining PCI-related myocardial infarction. 3 Incidence of PMI may vary depending on choice of bio-marker assay, cut-off values and frequencies of blood analyses. In non-selective multi-center series post procedural elevation of creatine kinase Myocardial band (CK-MB) mass and Cardiac Troponin I (cTn-I) above upper reference limit were found in 23±12% and 27±12% of patients respectively. 2 The overall incidence of post procedure CK-MB elevation was found in different studies were18.7%, 22.0% and 25.2%. [4] [5] [6] In one study periprocedural MI was found about 40%. 7 Different patient-related factors, lesion characteristics and procedure-related factors are considered as putative risk factors for PMI. 2, 5 Original Articles 
Different strategies have been proposed and tested to prevent peri-procedural myocardial infarction. Some clinical and experimental data suggest that 3-hydroxy-3-methylglutaryl co-enzyme A (HMGCoA) reductase inhibitors (statins) may exert antithrombotic effects, independent of cholesterol reduction, by affecting the vessel wall as well platelet function. Pre-procedural statin therapy was associated with a lower risk of troponin-I and CK-MB elevation after stent implantation. 2 Patients who have transient elevation in cardiac markers have higher mortality during extended follow up than those who did not and are independent of other predictors of mortality. 8 Among troponins, cTn-I is the most specific marker with a significant correlation, concordance and high predictive value for long-term event-free survival. The marker elevation per se may not be the primary cause of death but may be marker indicating greater plaque burden and relatively widespread atherosclerosis. These findings have important implications for daily interventional cardiology practice and highlight the risk associated with the common practice of overlooking or ignoring small infarctions as complication of PCI. 9 So, this study was undertaken to evaluate the protective effect of loading dose of atorvastatin in the reduction of peri-procedural myocardial injury during elective PCI.
Methods:
All patients admitted in the Department of Cardiology of NICVD, Dhaka fulfilling the criteria of inclusion was considered. History and clinical examination were carried out and recorded in pre designed structured proforma. Baseline investigations blood tests for angiogram were carried out for each of the patients.
Troponin I value was measured by Immulite 1000 Troponin I.(SIEMENS Medical Solutions Diagnostics, Los Angeles, CA, USA) on the day before the procedure and 24 hours after the procedure. Patients who had cTn-I >1 ng/ml was designated as having periprocedural myocardial injury and cTn-I >3 ng/ml was designated as having PCI related myocardial infarction.
12 lead resting ECG was done before sending the patient to cath lab, during the procedure, 01 hour after the procedure, next morning after the procedure. Coronary angiogram were evaluated for i) Stenosed vessels, number and degree of stenosis (expressed as percentage of occlusion, 0-100%), ii) Number of stenosed vessels was expressed as single/double/triple vessel diseases depending upon number of epicardial vessels to have significant stenosis and iii) Type of lesions expressed as Type I, II, III and IV according to ACC/AHA classification of lesion.
Patients were divided in two groups: The group I-treated with a loading dose of 80mg atorvastatin and group II-treated without a loading dose of 80mg atorvastatin. Data were noted-Length and diameter of stent, balloon and stent inflation pressure and total inflation time. Periprocedural events like side branch occlusion, coronary vasospasm, coronary dissection were noted.
Following the procedure, the patient was brought routinely to CCU for at least 24 hours where their hospital course and lab parameters were monitored. Patients were evaluated clinically and investigated for following complications: Persistent angina, new ischemic episode, non Q-wave MI, congestive cardiac failure, cardiac arrhythmia
Results:
This non-randomized controlled clinical trial was carried out in a total 100 consecutive patients were included in this study of which 50 patients were in the group I who were treated with a loading dose of 80mg atorvastatin and the rest 50 patients were in the group II who were treated without the loading dose of atorvastatin. The purpose of the study was to find the effect of loading dose of atorvastatin on the reduction of myocardial injury and infarction resulting from PCI and also to determine the beneficial effects of atorvastatin on peri-procedural outcome in PCI. The findings of the study obtained from data analysis are presented below. Table IV shows the distribution of ECG findings by groups. Ischemic change of ECG just after procedure is in 1 (2.0%) and 3 (6.0%) cases in group I and II respectively and ST changes during procedure was in 6 (12.0%) and 9 (18.0%) cases in group I and II respectively.There was no statistically significantdifference in ECG changes. 
Table-I Distribution of Risk factors by groups (n=100).
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Chandan Kumar Saha et al. Table V shows the distribution of procedural characteristics by groups. The mean diameter of stent, the mean length of stent, average balloon inflation pressure, mean total inflation time and the stent inflation pressure of stent were almost same in both group-I and group-II. Table VI shows the distribution of complications by groups. In Procedural complicationslike coronary spasm,side branch occlusion,coronary dissection and In-hospital complications like persistent angina,cardiac arrhythmia,myocardial infarction in both the groups were same. Table VII shows the distribution of Troponin-I level by groups. Troponin-I level 24 hours after PCI in less than 1 is found in45 (90.0%) cases and 7 (14.0%) cases in group I and group II respectively. Troponin-I level 24 hours after PCI in more than or equal to 1 is found in5 (10.0%) cases and 43 (86.0%) cases in group I and group II respectively. The mean± SD is found in 1.3± 0.5 and 1.8 ± 1.2 in group I and II respectively. So, mean cardiac Troponin-I level after stenting was significantly lower in group-I than that in the group-II patients (p=0.005).
Discussion:
In this study, the incidences of myonecrosis in patients undergoing elective PCI with or without pretreatment with atorvastatin were evaluated. Procedural and in hospital complications were also observed.
The distribution of study population according to age, sex and risk factors by groups is recorded in this study. No statistically significant difference was found between the two groups. The results were similar in some other studies. 6 There was no statistically significant difference in TIMI flow and ECG changes both before and after PCI prior to PCI and TIMI flow after PCI.The results were similar in some other studies. 10 In Procedural complications like coronary spasm, side branch occlusion,coronary dissection and inhospital complications like persistent angina,cardiac arrhythmia,myocardial infarction in both the groups were same. Similar pattern of post procedural complications were found in some studies. 6, 11 Coronary vasospasm was the most frequently encountered procedural complications. 5 Side branch occlusion was the commonest procedural complication followed by coronary dissection and spasm found in another study. 7 There were no significant differences found in this study regarding stent parameters, stent length and stent diameter between both groups.
The commonest ECG changes apart from premature ventricular complexes noted during the procedure was ST and T wave changes. Out of 100 patients, 6 (12%) in group-1 and 9 (18%) in group-II had ST segment changes during balloon inflation. T wave changes were noted about 6% and 8% in group I and group II respectively. The ST and T changes persisted in 4 patients (8%) after the procedure. Other ECG changes were sinus tachycardia and sinus bradycardia. The ECG changes both before and after PCI showed no statistically significant differences between group-I and group-II. 10 No patient needed to undergo repeat PCI or emergency CABG. There was also no significant difference noted regarding hospital stay and in hospital complications between two groups of patients.
The mean base line Troponin I (ng/ml) is 0.24 ± 0.12 and 0.21 ± 0.03 in group I and II respectively (p=0.088). Troponin-I level by groups is recorded before and after PCI in this study. Troponin-I level 24 hours after PCI in less than 1ng/ml is found more in group I (90.0%) than group II (14.0%). Whereas Troponin-I level after PCI in more than or equal to 1 is found more in group II (86.0%) than group I (10.0%). The mean± SD is found in 1.30 ± 0.50 and 1.80 ± 1.20 in group I and II respectively. So, mean cardiac Troponin-I level after stenting was significantly lower in group-I than that in the group-II patients (p=0.005). Significant benefit of statin pre-therapy on periprocedural elevation of Troponin-Iwas also demonstrated in many studies. [11] [12] [13] [14] In this study incidence of cTn-I rise following PCI was 86% without atorvastatin pretreatment and 10% with atorvastatin pretreatment. So the incidence of myonecrosis is less in atorvastatin pretreated group and the difference was statistically significant.
In the present study, the mean value of cTn-I rise at 24 hours following PCI was 1.3±0.5 ng/ml and 1.8±1.2 ng/ml in group I and group II respectively. This finding was statistically significant (p<0.005). Significant difference was also found in some studiesin regard to cTn-I level. 15
Conclusion:
From this study it is concluded that by measuring serum cardiac troponin I in patients undergoing PCI with pre medication with loading dose of atorvastatin is helpful in reducing post procedural myocardial injury and infarction. So, preprocedural loading dose of atorvastatin medication reduces the myocardial injury and infarction.
